53 related articles for article (PubMed ID: 20306032)
1. Pneumorrhachis With FDG Uptake Cervical Lesions on PET/CT of a Patient With Suspected Recurrent Hypopharyngeal Cancer.
Huang YE; Chuang CL; Wu SH; Chang YM; Kao PF
Clin Nucl Med; 2024 May; 49(5):462-463. PubMed ID: 38466017
[TBL] [Abstract][Full Text] [Related]
2. Cancer of the cervix uteri: 2021 update.
Bhatla N; Aoki D; Sharma DN; Sankaranarayanan R
Int J Gynaecol Obstet; 2021 Oct; 155 Suppl 1(Suppl 1):28-44. PubMed ID: 34669203
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic value of 18F-FDG-PET or PET-CT in recurrent cervical cancer: a systematic review and meta-analysis.
Chu Y; Zheng A; Wang F; Lin W; Yang X; Han L; Chen Y; Bai L
Nucl Med Commun; 2014 Feb; 35(2):144-50. PubMed ID: 24177043
[TBL] [Abstract][Full Text] [Related]
4. Diagnosis of recurrent uterine cervical cancer: PET versus PET/CT: a systematic review and meta-analysis.
Ding XP; Feng L; Ma L
Arch Gynecol Obstet; 2014 Oct; 290(4):741-7. PubMed ID: 24798933
[TBL] [Abstract][Full Text] [Related]
5. Clinical and survival impact of FDG PET in patients with suspicion of recurrent cervical carcinoma.
Pallardy A; Bodet-Milin C; Oudoux A; Campion L; Bourbouloux E; Sagan C; Ansquer C; Testard A; Resche I; Bridji B; Kraeber-Bodéré F; Rousseau C
Eur J Nucl Med Mol Imaging; 2010 Jul; 37(7):1270-8. PubMed ID: 20306032
[TBL] [Abstract][Full Text] [Related]
6. Clinical impact of integrated PET/CT on the management of suspected cervical cancer recurrence.
Chung HH; Jo H; Kang WJ; Kim JW; Park NH; Song YS; Chung JK; Kang SB; Lee HP
Gynecol Oncol; 2007 Mar; 104(3):529-34. PubMed ID: 17049971
[TBL] [Abstract][Full Text] [Related]
7. Prospective evaluation of 18F-fluorodeoxyglucose positron emission tomography-computed tomography for response evaluation in recurrent carcinoma cervix: does metabolic response predict survival?
Dhull VS; Sharma P; Sharma DN; Maharjan S; Suman Kc S; Patel C; Bal C; Kumar R
Int J Gynecol Cancer; 2014 Feb; 24(2):312-20. PubMed ID: 24407578
[TBL] [Abstract][Full Text] [Related]
8. Clinical value of FDG PET/CT in the diagnosis of suspected recurrent ovarian cancer: is there an impact of FDG PET/CT on patient management?
Bilici A; Ustaalioglu BB; Seker M; Canpolat N; Tekinsoy B; Salepci T; Gumus M
Eur J Nucl Med Mol Imaging; 2010 Jul; 37(7):1259-69. PubMed ID: 20309683
[TBL] [Abstract][Full Text] [Related]
9. Comparative benefits and limitations of 18F-FDG PET and CT-MRI in documented or suspected recurrent cervical cancer.
Yen TC; Lai CH; Ma SY; Huang KG; Huang HJ; Hong JH; Hsueh S; Lin WJ; Ng KK; Chang TC
Eur J Nucl Med Mol Imaging; 2006 Dec; 33(12):1399-407. PubMed ID: 16847653
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of 18F-FDG PET/CT in the evaluation of patients with recurrent cervical carcinoma.
Mittra E; El-Maghraby T; Rodriguez CA; Quon A; McDougall IR; Gambhir SS; Iagaru A
Eur J Nucl Med Mol Imaging; 2009 Dec; 36(12):1952-9. PubMed ID: 19585114
[TBL] [Abstract][Full Text] [Related]
11. Clarifying the diagnosis of clinically suspected recurrence of cervical cancer: impact of 18F-FDG PET.
van der Veldt AA; Buist MR; van Baal MW; Comans EF; Hoekstra OS; Molthoff CF
J Nucl Med; 2008 Dec; 49(12):1936-43. PubMed ID: 18997039
[TBL] [Abstract][Full Text] [Related]
12. Surveillance FDG-PET detection of asymptomatic recurrences in patients with cervical cancer.
Brooks RA; Rader JS; Dehdashti F; Mutch DG; Powell MA; Thaker PH; Siegel BA; Grigsby PW
Gynecol Oncol; 2009 Jan; 112(1):104-9. PubMed ID: 18929403
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic accuracy of integrated FDG-PET/contrast-enhanced CT in staging ovarian cancer: comparison with enhanced CT.
Kitajima K; Murakami K; Yamasaki E; Kaji Y; Fukasawa I; Inaba N; Sugimura K
Eur J Nucl Med Mol Imaging; 2008 Oct; 35(10):1912-20. PubMed ID: 18682935
[TBL] [Abstract][Full Text] [Related]
14. Association of posttherapy positron emission tomography with tumor response and survival in cervical carcinoma.
Schwarz JK; Siegel BA; Dehdashti F; Grigsby PW
JAMA; 2007 Nov; 298(19):2289-95. PubMed ID: 18029833
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
